Bio-Rad Laboratories, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bio-Rad Laboratories, Inc.
Dealmaking Quarterly Statistics, Q3 2022
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Tech Transfer Roundup: Amylyx Goes Pipeline Hunting While Seeking US Approval Of ALS Candidate
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
Bill Would Make US FDA Issue Final Rule On Risk Information In Broadcast DTC Ads
Proposed rule issued in March 2010 requires ‘major statement’ on a drug’s side effects in ‘a clear, conspicuous, and neutral manner’ for TV and radio ads. Bill would mandate a final rule within six months.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
- In Vitro Diagnostics
- Medical Devices
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
- AbD Serotec
- Celsee, Inc.
- Curiosity Diagnostics, Sp. Z. o. o.
- SafePath Laboratories
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.